AACR 2021 | ctDNA and cfDNA : prognostic value in the neoadjuvant setting of colon cancer

Giacomo Bregni, MD, Jules Bordet Institute, Brussels, Belgium, talks on the prognostic value of circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) for patients with colon cancer in the neoadjuvant setting. Dr Bregni outlines a study which analysed the prognostic value of ctDNA and cfDNA in patients with early-stage colon cancer who were treated with one cycle of FOLFOX chemotherapy followed by surgery with or without adjuvant FOLFOX in the PePiTA trial (NCT00994864). The study found that baseline cfDNA may be a predictor of survival outcomes in this group of patients. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.